Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Změna mozkové perfuze během úvodu do celkové anestezie (CERVO2)

8. října 2026 aktualizováno: Assistance Publique - Hôpitaux de Paris

Změna mozkové perfuze během úvodu do celkové anestezie: Vztah mezi transkraniálním dopplerem, bispektrálním indexem a cerebrální oxymetrií: prospektivní observační studie CERVO2

Arterial hypotension during general anesthesia remains a factor of poor outcomes, increases the risk of myocardial infarction, acute kidney injury and 1-year mortality. Furthermore, arterial hypotension may also decrease cerebral perfusion contributing to worsen neurological outcome. It seems necessary to monitor cerebral perfusion during anesthesia and to define individual dynamic targets of blood pressure. The goal of this study is to evaluate cerebral perfusion change in adult patients with or without cardiovascular risk factors during a standardized propofol-remifentanil anesthesia induction. Cerebral perfusion will be evaluated and compared by simultaneous measurements of cerebral blood flow, cerebral oxygen saturation and neurological function with use of transcranial Doppler (TCD), Near infrared spectroscopy (NIRS) and the Bispectral index (BIS) monitoring, respectively. Those measurements will be also repeated during and after treatment of arterial hypotension episodes in both groups.

Přehled studie

Postavení

Ukončeno

Podmínky

Intervence / Léčba

Detailní popis

Main objective: blood pressure target to maintain cerebral perfusion is related to patient's characteristics or comorbidities, it remains uncertain which threshold of blood pressure is to use during general anesthesia in each specific case. Thus, it seems necessary to monitor the cerebral perfusion during anesthesia and to determine the individual dynamic targets of blood pressure. The measure of middle cerebral artery blood flow velocity by transcranial doppler (TCD) is a clinical method to assess cerebral perfusion during general anesthesia and several studies have reported the hemodynamic impact on cerebral blood flow during induction.

Cerebral perfusion can also be approached by near infrared spectroscopy (NIRS) which measures continuously cerebral oxygen saturation. Bispectral index (BIS), which allows a simplified form of continuous electroencephalogram monitoring to assess depth of anesthesia, could also provide the cerebral hypoperfusion assessment quantified by the count of burst suppression ratio (SR). Potentially, those tools need to be combined to assess cerebral perfusion properly.

The goal of this study is to evaluate cerebral perfusion change in adult participants with or without cardiovascular risk factors during a standardized propofol-remifentanil anesthesia induction. Cerebral perfusion will be evaluated and compared using simultaneously the TCD, NIRS and BIS measurements. Those measurements will be also repeated during and after treatment of arterial hypotension episodes in both groups.

Population concerned : the study involves major patients who benefit from intraoperative hemodynamic optimization with norepinephrine (as noradrenaline tartrate) for maintaining blood pressure under general anesthesia during an interventional neuroradiology procedure or orthopedic surgery.

Research Proceedings: all monitoring (TCD, BIS, NIRS) will be collected from the healthy side, contralateral to the interventional side. BIS, NIRS and continuous non-invasive blood pressure measurement will be all connected to the main monitor. For all participants, the data from TCD, NIRS, BIS and the hemodynamic data will be collected over three distinct periods of the interventional procedure : (1) baseline or during preoxygenation at FiO2 of 21% (fraction of inspired oxygen) in awake patients, (2) before Orotracheal Intubation and (3) just after mechanical ventilation.

In patients presenting a hypotensive episode at any time of the procedure, all parameters will be collected before and at the peak effect after a 10μg bolus injection of norepinephrine.

Patients will be assigned to one of two groups according to the presence of cardiovascular risk factors. Major risk factor is age > 50 years old. Minor risk factors include history of congestive heart failure, history of cardiovascular event, current smoking, diabetes mellitus, dyslipidemia, arterial hypertension. Patients will be classified into the high-risk group (Hi-risk) if they have at least one major cardiovascular risk factor or two minor factors, or into the low risk group (Lo-risk) if they present one minor or no risk factors.

During their interventional neuroradiology procedure or orthopedic surgery, all patients' routine monitoring will consist in collecting the following parameters: electrocardiogram, pulsated oxygen saturation, endtidal CO2, respiratory rate, tidal volume and neuromuscular function.

For all patients whatever the comorbidities, anesthesia induction will be performed using a target-controlled infusion (Orchestra® Base Primea - Fresenius Kabi France). According to our standard of care, intra-operative episodes of hypotension (mean arterial pressure (MAP) < 65 mmHg or < 80% baseline) will be treated by Norepinephrine bolus of 10 μg.

Statistics: Changes in parameters across the time, during induction and/or during vasopressors boluses will be tested by using a paired Student-t test after testing the normality of the distribution. Correlation between the change in MAP and Vm during induction will be done using Spearman test. Complete analysis will also be performed to compare the Low-risk and High-risk patients. The analysis of vasopressor boluses will be performed depending on the time of administration: boluses which are given immediately after induction of anesthesia (early) and boluses given after a 30 minutes period of constant intravenous calculated concentrations of anesthesia (late). All statistical analyses will be performed using R statistical software (The 'R' Foundation for Statistical Computing, Vienna, Austria). Results will be expressed as means (± SD). A two sided p value of 0.05 will be considered significant.

The sample size calculation is based on the following assumptions: incidence of Hi-risk patients of 50%, as previously reported; incidence of burst suppression during induction in low risk patients of 20%; difference of incidence of burst suppression between low- and high-risk patients of 30%; power at 80% and type I error at 5%. Accordingly, the calculated sample size is 101 patients for the entire population.

Typ studie

Pozorovací

Zápis (Aktuální)

68

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Paris, Francie, 75010
        • AP-HP, Lariboisière Hospital, Department of Anesthesiology and Intensive Care

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

The study involves major patients who benefit from intraoperative hemodynamic optimization with norepinephrine (as noradrenaline tartrate) for maintaining blood pressure under general anesthesia during an interventional neuroradiology procedure or orthopedic surgery.

Popis

Inclusion Criteria:

  • Major patients (≥ 18 years old)
  • Eligible for an interventional radiology procedure or orthopedic surgery under general anesthesia.
  • Patients who expressed their non-opposition to participation in this research

Exclusion Criteria:

  • Patients under the age of 18.
  • Patient opposed to participation in the protocol
  • Pregnant woman
  • Patient under judicial protection measure
  • Patient without affiliation to a social security scheme-

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Interventional radiology or surgery under general anesthesia

Monitoring of patients (mean arterial blood pressure, Transcranial Doppler , bispectral index, near infrared spectroscopy) who benefit from intraoperative hemodynamic optimization with norepinephrine (as noradrenaline tartrate) for maintaining blood pressure under general anaesthesia during the interventional neuroradiology or orthopedic surgery in adults .

For all patients, mean arterial pressure (unit mmHg) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.

Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography.

For all patients, CFV (unit cm/s) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.

Continuous measurement of burst suppression (BS; %) with use of Bispectral Index (BIS).

For all patients, BS will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation

Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).

For all patients, SO2 (%) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Mean arterial blood pressure
Časové okno: Duration of the surgical intervention or interventional neuroradiology procedure (maximum 1 day)

For all patients, the mean arterial pressure (unit mmHg) will be collected continuously, over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation

Duration of the surgical intervention or interventional neuroradiology procedure (maximum 1 day)
Cerebral blood flow velocity
Časové okno: Duration of the surgical intervention or interventional neuroradiology procedure (maximum 1 day)

For all patients, CFV (unit cm/s) will be collected continuously, using Transcranial Doppler, over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.

Duration of the surgical intervention or interventional neuroradiology procedure (maximum 1 day)
Burst Suppression
Časové okno: Duration of the surgical intervention or interventional neuroradiology procedure (maximum 1 day)

Continuous measurement of burst suppression (BS; %) with use of Bispectral Index (BIS) over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.

Duration of the surgical intervention or interventional neuroradiology procedure (maximum 1 day)
Cerebral oxygen saturation
Časové okno: Duration of the surgical intervention or interventional neuroradiology procedure (maximum 1 day)

For all patients, the cerebral oxygen saturation (SO2; %) will be collected continuously, using Near-infrared spectroscopy, over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.

Duration of the surgical intervention or interventional neuroradiology procedure (maximum 1 day)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Vyšetřovatelé

  • Ředitel studie: Joaquim MATEO, MD, Assistance Publique - Hôpitaux de Paris
  • Vrchní vyšetřovatel: Fabrice VALLEE, MD, Assistance Publique - Hôpitaux de Paris

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

27. ledna 2021

Primární dokončení (Aktuální)

10. října 2022

Dokončení studie (Aktuální)

10. října 2022

Termíny zápisu do studia

První předloženo

26. února 2020

První předloženo, které splnilo kritéria kontroly kvality

26. února 2020

První zveřejněno (Aktuální)

28. února 2020

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

14. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

8. října 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • APHP190945
  • 2019-A02516-51 (Jiný identifikátor: IDRCB)

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .